ProQR Therapeutics BV Net Assets
ProQR Therapeutics BV net assets. Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has net assets worth $79.44 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($133.50 Million) and total liabilities ($54.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of ProQR Therapeutics BV to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $79.44 Million |
| % of Total Assets | 59.51% |
| Annual Growth Rate | 59.84% |
| 5-Year Change | -54.97% |
| 10-Year Change | 3.47% |
| Growth Volatility | 77.29 |
Net Assets of ProQR Therapeutics BV (2012–2025)
Net assets of ProQR Therapeutics BV from 2012 to 2025. This chart illustrates how ProQR Therapeutics BV's net assets have evolved over time, based on quarterly financial data. See PRQR equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for ProQR Therapeutics BV (2012–2025)
The table below shows the annual net assets of ProQR Therapeutics BV from 2012 to 2025. For live market cap and overall valuation, see ProQR Therapeutics BV market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $57.99 Million | -36.77% |
| 2024-12-31 | $91.70 Million | +100.57% |
| 2023-12-31 | $45.72 Million | -35.75% |
| 2022-12-31 | $71.17 Million | -44.73% |
| 2021-12-31 | $128.76 Million | +86.11% |
| 2020-12-31 | $69.19 Million | -34.31% |
| 2019-12-31 | $105.33 Million | +13.64% |
| 2018-12-31 | $92.69 Million | +96.28% |
| 2017-12-31 | $47.22 Million | -15.74% |
| 2016-12-31 | $56.05 Million | -42.55% |
| 2015-12-31 | $97.55 Million | -26.31% |
| 2014-12-31 | $132.38 Million | +108047.22% |
| 2013-12-31 | $-122.64K | -193.96% |
| 2012-12-31 | $130.52K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProQR Therapeutics BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54851133000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ProQR Therapeutics BV Net Assets Breakdown (December 2025)
ProQR Therapeutics BV net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.06 Million | 8.73% |
| Other Comprehensive Income | $33.70 Million | 58.11% |
| Other Components | $568.29 Million | 980.03% |
| Total Equity | $57.99 Million | 100.00% |
ProQR Therapeutics BV Competitors by Market Cap
The table below lists competitors of ProQR Therapeutics BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Multikarya Asia Pacific Ray
JK:MKAP
|
$199.01 Million |
|
TTFB Co Ltd
TWO:2729
|
$199.02 Million |
|
Nextgreen Global Bhd
KLSE:7241
|
$199.03 Million |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
$199.06 Million |
|
KOSKISEN OYJ EO 1
F:EZ8
|
$198.87 Million |
|
Wildcat Resources Ltd
AU:WC8
|
$198.85 Million |
|
NorAm Drilling AS
F:TM9
|
$198.83 Million |
|
Ndr Auto Components Limited
NSE:NDRAUTO
|
$198.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProQR Therapeutics BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 91,703,880 to 57,987,294, a change of -33,716,586 (-36.8%).
- Net loss of 40,519,110 reduced equity.
- Other comprehensive income increased equity by 5,118,415.
- Other factors increased equity by 1,684,109.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.52 Million | -69.88% |
| Other Comprehensive Income | $5.12 Million | +8.83% |
| Other Changes | $1.68 Million | +2.9% |
| Total Change | $- | -36.77% |
Book Value vs Market Value Analysis
This analysis compares ProQR Therapeutics BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 64.82x to 2.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.02 | $1.41 | x |
| 2013-12-31 | $-0.01 | $1.41 | x |
| 2014-12-31 | $5.98 | $1.41 | x |
| 2015-12-31 | $4.18 | $1.41 | x |
| 2016-12-31 | $2.40 | $1.41 | x |
| 2017-12-31 | $1.86 | $1.41 | x |
| 2018-12-31 | $2.72 | $1.41 | x |
| 2019-12-31 | $2.58 | $1.41 | x |
| 2020-12-31 | $1.40 | $1.41 | x |
| 2021-12-31 | $2.02 | $1.41 | x |
| 2022-12-31 | $1.00 | $1.41 | x |
| 2023-12-31 | $0.56 | $1.41 | x |
| 2024-12-31 | $1.12 | $1.41 | x |
| 2025-12-31 | $0.55 | $1.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProQR Therapeutics BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -265.21%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 2.28x
- Recent ROE (-69.88%) is below the historical average (-50.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -2033.13% | 0.03x | 0.00x | $-3.24 Million |
| 2014 | -9.16% | -3874.44% | 0.00x | 1.05x | $-25.37 Million |
| 2015 | -21.36% | -221.45% | 0.09x | 1.11x | $-30.59 Million |
| 2016 | -69.77% | -1713.54% | 0.03x | 1.23x | $-44.71 Million |
| 2017 | -92.32% | 0.00% | -0.02x | 1.35x | $-48.36 Million |
| 2018 | -39.81% | -746.69% | 0.04x | 1.19x | $-46.16 Million |
| 2019 | -53.59% | -2935.64% | 0.01x | 1.25x | $-67.33 Million |
| 2020 | -66.66% | -4525.27% | 0.01x | 1.73x | $-53.55 Million |
| 2021 | -46.92% | -4549.81% | 0.01x | 1.84x | $-73.69 Million |
| 2022 | -90.01% | -1792.54% | 0.02x | 2.55x | $-71.58 Million |
| 2023 | -61.50% | -431.67% | 0.04x | 3.33x | $-32.69 Million |
| 2024 | -30.27% | -146.86% | 0.11x | 1.90x | $-36.93 Million |
| 2025 | -69.88% | -265.21% | 0.12x | 2.28x | $-46.32 Million |
Industry Comparison
This section compares ProQR Therapeutics BV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProQR Therapeutics BV (PRQR) | $79.44 Million | 0.00% | 0.68x | $198.98 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more